Background. The purpose of the work was to investigate remote and preventive results of sublingual allergenspecific immunotherapy (SLiT) at pollinosis patients. Methods. 25 patients at the age from 19 till 50 years old with an allergic rhinitis and asthma (35%) sensitized to artemisia were under the supervision. SLiT was administered in the period since September 2003 till May 2006 with pollen allergen («Sevapharma», Czech Republik). The average total dose of the allergen per one patient at the end of the third year was 189999 PNU. Clinical efficiency was estimated annually and in 30 months after discontinuation of SLiT. Frequency and intensity of symptoms during the pollen season, requirement for medicines, FEV1 parameters and results of prick tests were considered. Results. good and excellent results after three courses of immunotherapy demonstrated 23 patients (92%), satisfactory - 2 patients (8%). The results were remained at 22 patients (88%) within the next 30 months. at 3 patients (12%) increase of rhinoconjunctivitis symptoms was noted, and 3 (12%) showed expansion of a sensibilisation spectrum. Further increase of intensity and frequency of asthma symptoms, decrease in indicators FEV1 was not registered. Conclusion. SLiT is a highly effective method of treatment for patients with seasonal rhinitis and leads to the clinical results remaining more than 2 years at the majority of patients.